University of Bradford to bridge East and West in collaborative r&d programme
The University of Bradford is to launch its China Science Bridges programme this week, which will focus on collaborative r&d between the two nations" scientists and pharmaceutical companies to develop new therapies, medical diagnostics and devices.
The University of Bradford is to launch its China Science Bridges programme this week, which will focus on collaborative r&d between the two nations" scientists and pharmaceutical companies to develop new therapies, medical diagnostics and devices.
The programme, which has won £1.3m funding from Research Councils UK, will provide opportunities for bridging East and West, from fundamental research to the establishment of promising new companies.
The Science Bridges programme involves three of the University of Bradford's leading research areas: the Institute of Pharmaceutical Innovation, the Institute of Cancer Therapeutics and the Polymer Interdisciplinary Research Centre. It will focus on the development of products in areas of priority to both governments such as diabetes, infection control, traditional Chinese medicine and medical devices.
"Through this programme we hope to be able to bring new therapies and healthcare technologies to market, forging stronger links between Eastern and Western approaches to medicine, and taking steps towards implementing new solutions to combat diseases such as cancer, diabetes and malaria," said Phil Coates, pro-vice-chancellor for Research, Innovation and Knowledge Transfer, at the University of Bradford.
The programme aims to accelerate product invention, design and development and will focus on three main activities: an "Open Innovation" project scheme to develop prototypes and products, reciprocal training programmes and developing state-of-the-art knowledge and commercial networks.
Further funding has been made in China, including support for research programmes at the University of Bradford's partner institutes Tsinghua, Shanghai IMM CAS for drug delivery projects, and Sichuan for a biomedical materials project, and to local government support, initially in Changzhou for Open Innovation programmes in China.
